Earth Science Tech Inc. (ETST) Reports Transformational Fiscal Year as Share Repurchases and Healthcare Expansion Shape Growth Strategy

• Earth Science Tech, a growing holding company focused on various aspects of the healthcare industry, reported a series of operational milestones in its fiscal year ended March 31, 2026, highlighted by expansion across its healthcare platform and continued cash-flow generation.
• Earth Science Tech repurchased and retired more than 6.9 million shares of common stock since fiscal Q1 2026, underscoring management’s focus on reducing share dilution in support of shareholder value.
• Key operating businesses, including DOConsultation, Villas Health and MOC Teledoc, are now cash-flow positive.
• Peaks Curative surpassed $2 million in revenue during the first week of fiscal Q4 2026, reflecting growth within the company’s health and wellness segment.
• Management emphasized that expansion initiatives were completed without adding debt to the balance sheet, maintaining a disciplined capital structure.
• Investors will have an opportunity to hear directly from management when CEO Giorgio R. Saumat presents at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17.

Earth Science Tech (OTC: ETST), a strategic healthcare-oriented holding company, has spent the past several years reshaping itself from a wellness-focused enterprise into a diversified holding company centered on healthcare, pharmaceutical compounding, telemedicine, real estate, and cash-flow-generating operating businesses. That transformation was a central theme of the company’s annual shareholder letter for the fiscal year ended March 31, 2026, where management highlighted operational progress, balance-sheet discipline, and an ongoing share repurchase strategy that has become a defining element of ETST’s capital allocation approach (https://ibn.fm/WX3CI).

In the letter, CEO and Chairman Giorgio R. Saumat described fiscal 2026 as a year in which the company strengthened the foundation for future growth while maintaining a debt-free approach to expansion.

Several milestones stood out. Among them was the continued development of Mister Meds, a Texas-based healthcare operation housed in a property previously acquired by the company. Management noted that the facility was built out and brought into operation without adding debt to the balance sheet.

The company also reported successful turnarounds of DOConsultation and Villas Health, both of which are now cash-flow positive according to management. These businesses play an important role within ETST’s broader healthcare ecosystem, which is designed to integrate telemedicine services, clinical support, prescription fulfillment, and pharmacy operations under a single corporate structure.

That vertical integration strategy remains a central part of the investment thesis surrounding the company. By controlling multiple stages of the patient journey, from consultation and diagnosis through prescription fulfillment and ongoing care, Earth Science Tech seeks to capture value across the healthcare continuum rather than relying on a single service line. Management believes this approach improves operational efficiency while increasing patient retention and lifetime value.

Another important development during the fiscal year was the relaunch of MyOnlineConsultation, also known as MOC Teledoc. The company rebuilt its proprietary technology infrastructure and repositioned the platform as a prescriber network. According to management, the operation has been cash-flow positive since its launch.

Meanwhile, Peaks Curative, another subsidiary within the ETST portfolio, recorded significant growth. Management reported that the business exceeded $2 million in revenue during the first week of the company’s fourth fiscal quarter, an achievement highlighted in the shareholder letter as evidence of increasing momentum across the health and wellness segment.

While operational performance attracted attention, the company’s capital allocation strategy is of particular interest. Earth Science Tech has consistently emphasized balance-sheet strength and shareholder value creation through share repurchases and share retirement programs.

During fiscal 2026, the company repurchased and retired 3,773,296 shares of common stock. In addition, management disclosed that another 3,150,392 shares had been retired during the current fiscal year-to-date period, bringing total repurchases and retirements since fiscal Q1 2026 to more than 6.9 million shares. For shareholders, reducing outstanding share count can help mitigate dilution while increasing ownership concentration among remaining investors.

The approach stands in contrast to many small-cap growth companies that frequently rely on equity issuance to fund expansion. ETST has repeatedly stressed that its acquisitions, operational improvements, infrastructure investments, and share repurchases have been completed without adding debt to the balance sheet. That emphasis on capital discipline appears throughout management’s communications.

In the shareholder letter, Saumat repeatedly referenced the company’s debt-free growth strategy, describing it as a key differentiator as ETST continues expanding its operating footprint.

Looking ahead, management indicated that the company will begin reporting results across two primary segments: Health/Wellness and Corporate/Other. The Health/Wellness segment is expected to remain the primary revenue driver and includes telemedicine, pharmacy-related activities, healthcare services, and associated operations. The Corporate/Other segment includes real estate development activities and broader asset management initiatives. The company also disclosed that three additional development properties are currently awaiting final permit approval, reflecting continued activity beyond healthcare operations.

Earth Science Tech also recently announced that Saumat will present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17 at the Bellagio Resort & Hotel. The presentation will include a live question-and-answer session, and management will also be available for one-on-one meetings with investors throughout the event (https://ibn.fm/pAxrU).

“I look forward to meeting shareholders at the Planet Microcap Conference in Las Vegas on June 16th – 18th or at our annual shareholder meeting (date TBD – after we file our 10-K annual report),” Saumat said in conclusion of the letter to shareholders. “As we set our sights on the milestones ahead, we remain fiercely committed to transparency and to a relentless focus on maximizing shareholder value.”

For more information, visit the company’s website at www.EarthScienceTech.com.

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN